262 related articles for article (PubMed ID: 34285711)
1. Exploring the Mystery of Angiotensin-Converting Enzyme II (ACE2) in the Battle against SARS-CoV-2.
Sharma D; Sharma J; Singh A
J Renin Angiotensin Aldosterone Syst; 2021; 2021():9939929. PubMed ID: 34285711
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.
Xu B; Li G; Guo J; Ikezoe T; Kasirajan K; Zhao S; Dalman RL
J Vasc Surg; 2021 Nov; 74(5):1740-1751. PubMed ID: 33600934
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases.
Sharma RK; Li J; Krishnan S; Richards EM; Raizada MK; Mohandas R
Clin Sci (Lond); 2021 Jan; 135(1):1-17. PubMed ID: 33399851
[TBL] [Abstract][Full Text] [Related]
5. Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.
Herman-Edelstein M; Guetta T; Barnea A; Waldman M; Ben-Dor N; Barac YD; Kornowski R; Arad M; Hochhauser E; Aravot D
Cardiovasc Diabetol; 2021 Apr; 20(1):90. PubMed ID: 33906662
[TBL] [Abstract][Full Text] [Related]
6. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
7. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes.
Guney C; Akar F
J Pharm Pharm Sci; 2021; 24():84-93. PubMed ID: 33626315
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.
Oz M; Lorke DE
Biomed Pharmacother; 2021 Apr; 136():111193. PubMed ID: 33461019
[TBL] [Abstract][Full Text] [Related]
9. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
Parit R; Jayavel S
Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
[TBL] [Abstract][Full Text] [Related]
10. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
[TBL] [Abstract][Full Text] [Related]
11. Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract.
Galanopoulos M; Doukatas A; Gazouli M
World J Gastroenterol; 2020 Nov; 26(41):6335-6345. PubMed ID: 33244196
[TBL] [Abstract][Full Text] [Related]
12. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Verdecchia P; Cavallini C; Spanevello A; Angeli F
Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
[TBL] [Abstract][Full Text] [Related]
13. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
14. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
Oz M; Lorke DE; Kabbani N
Pharmacol Ther; 2021 May; 221():107750. PubMed ID: 33275999
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Hu Y; Liu L; Lu X
Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
[TBL] [Abstract][Full Text] [Related]
17. Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.
Wang Q; Qiu Y; Li JY; Liao CH; Zhou ZJ; Ge XY
Transbound Emerg Dis; 2021 May; 68(3):1046-1053. PubMed ID: 32794346
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
19. Classical and alternative receptors for SARS-CoV-2 therapeutic strategy.
Masre SF; Jufri NF; Ibrahim FW; Abdul Raub SH
Rev Med Virol; 2021 Sep; 31(5):1-9. PubMed ID: 33368788
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.
Cells; ; . PubMed ID: 34359983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
